The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Business Wire

Teva Calls 5.550% Senior Notes Due 2016 for Redemption

Friday, March 01, 2013

Teva Calls 5.550% Senior Notes Due 2016 for Redemption09:18 EST Friday, March 01, 2013 JERUSALEM (Business Wire) -- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that its finance subsidiary Teva Pharmaceutical Finance Company, LLC has called for redemption its approximately $500 million outstanding principal amount of 5.550% Senior Notes due 2016 (CUSIP No. 88163V AC3). The redemption is being funded with cash on hand. The redemption date will be March 22, 2013, and the redemption price will equal the principal amount of the notes plus a make whole premium calculated in accordance with the terms of the applicable indenture. On the redemption date, the redemption price, together with accrued and unpaid interest from February 1, 2013, to, but excluding, the redemption date, will become due and payable on the notes. Details concerning the redemption price and the other terms and conditions of the redemption will be more fully described in a Notice of Redemption being provided to registered holders of the notes by The Bank of New York Mellon, as trustee. Holders of notes who have questions should contact Joellen McNamara of The Bank of New York Mellon at 1-212-815-5587 or via email at joellen.mcnamara@bnymellon.com, or Teva's investor relations department at (215) 591-8912 or (011) 972-3-926-7656. About Teva Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $20.3 billion in net revenues in 2012. Teva Pharmaceutical Industries Ltd.IR:United StatesKevin C. Mannix, 215-591-8912Kristen Frank, 215-591-8908orIsraelTomer Amitai, 972 (3) 926-7656orPR:IsraelHadar Vismunski-Weinberg, 972 (3) 926-7687orUnited StatesDenise Bradley, 215-591-8974